Result of AGM

RNS Number : 6981Q

Polarean Imaging PLC

29 June 2022

 

Polarean Imaging Plc

("Polarean" or the "Company")

Result of AGM

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with an investigational drug‑device combination product using hyperpolarised ¹²⁹ xenon gas to enhance magnetic resonance imaging (MRI) in pulmonary medicine, announces that at the AGM held earlier today, all resolutions were duly passed.

Details of the proxy votes received on each resolution by Polarean's Registrar are set out below:

Resolution	For	Against
01	81,431,955	1,031,207
02	73,318,568	7,233,350
03	82,445,663	17,499
04	82,443,685	19,267
05	68,134,930	3,012,962
06	75,246,807	7,216,145
07	75,246,807	7,216,145
08	82,359,153	93,622
09	75,113,835	7,329,416

Enquiries:

Polarean Imaging plc			www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer			Via Walbrook PR
Ken West, Chairman
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)				[phone]
Nicholas Moore / Samira Essebiyea / William Palmer-Brown (Healthcare Investment Banking)
Nick Adams / Fred Walsh (Corporate Broking)
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy /Phillip Marriage		Mob: [phone]

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (¹²⁹Xe) as an imaging agent to visualise ventilation. ¹²⁹Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised ¹²⁹Xe used to evaluate pulmonary function and to visualise the lung using MRI. The Group received a complete response letter on 5 October 2021. On 30 March 2022, the Company filed the resubmission of its NDA with the US FDA and has received a PDUFA date of Sept 30, 2022.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.

 

END

 

 

RAGSEEFIUEESEDM